Synonyms for perimenopause or Related words with perimenopause

postmenopause              perimenopausal              menarche              andropause              oligomenorrhea              menopause              climacteric              hypoestrogenism              metrorrhagia              menopausal              premenopause              menstruation              polymenorrhea              gynecomastia              hypermenorrhea              anovulatory              premenopausal              gonadarche              subfertility              anovulation              menstruating              menorrhagia              oligoovulation              pubertal              menstruations              puberty              thelarche              hypomenorrhea              puerperium              childbirth              oligomenorrhoea              mastodynia              ovulatory              galactorrhoea              postandropausal              postmenopausal              coitus              hyperandrogenemia              hsdd              hysterectomised              parturition              dysmenorrheic              adolescence              adrenarche              adenomyosis              anorgasmia              ohss              virilism              amenorrhoea              masculinization             



Examples of "perimenopause"
Perimenopause is a natural stage of life. It is not a disease or a disorder. Therefore, it does not automatically require any kind of medical treatment. However, in those cases where the physical, mental, and emotional effects of perimenopause are strong enough that they significantly disrupt the life of the woman experiencing them, palliative medical therapy may sometimes be appropriate.
The menopause transition typically begins between 40 and 50 years of age (average 47.5). The duration of perimenopause may be for up to eight years. Women will often, but not always, start these transitions (perimenopause and menopause) about the same time as their mother did.
Oligomenorrhea can be a result of prolactinomas (adenomas of the anterior pituitary). It may be caused by thyrotoxicosis, hormonal changes in perimenopause, Prader–Willi syndrome, and Graves disease.
During perimenopause symptoms often get worse before decreasing in severity. While symptoms resolve in about two thirds of the elderly, in between 3 and 10% they persist.
Dr. Jerilynn C. Prior is an American-born, Canadian endocrinologist and medical doctor specializing in menstrual cycles and the effects of hormones on women's health. She has been called a leader in understanding and treating perimenopause and menopause.
Houston's inspiration for the film came after three years of battling a range of health issues related to menopause and its precursor, perimenopause. There are currently over 1 billion women in menopause and over 1.5 billion women in perimenopause. The women interviewed in the documentary talk about their sex lives with candor and humor. The film addresses the use of hormone therapy to treat the symptoms of menopause and confronts the 2002 Women's Health Initiative study that led women to forgo estrogen-replacement medications and, in some cases, jeopardize their health.
During perimenopause, estrogen levels average about 20–30% higher than during premenopause, often with wide fluctuations. These fluctuations cause many of the physical changes during perimenopause as well as menopause. Some of these changes are hot flashes, night sweats, difficulty sleeping, vaginal dryness or atrophy, incontinence, osteoporosis, and heart disease. During this period, fertility diminishes but is not considered to reach zero until the official date of menopause. The official date is determined retroactively, once 12 months have passed after the last appearance of menstrual blood.
Ovarian fibromas represent 4% of all ovarian neoplasms. They tend to occur mostly during perimenopause and postmenopause, the median age having been reported to be about 52 years, and they are rare in children. Lesions tend to be asymptomatic. If symptoms are present, the most common one is abdominal pain.
One of the most common causes of night sweats in women over 40 is the hormonal changes related to menopause and perimenopause. This is a very common occurrence during the menopause transition years and while annoying, it is not necessarily dangerous or a sign of underlying disease.
Estrogen is considered to play a significant role in women’s mental health. Sudden estrogen withdrawal, fluctuating estrogen, and periods of sustained estrogen low levels correlate with significant mood lowering. Clinical recovery from postpartum, perimenopause, and postmenopause depression has been shown to be effective after levels of estrogen were stabilized and/or restored.
The film, narrated by Goldie Hawn, describes the journey through perimenopause, menopause and into post-menopause by examining in-depth personal experiences of women and featuring relevant perspectives by medical experts. Presented by Iron Rose Films, it is directed by Marc Bennett, produced by Heidi Houston, written by Marnie Inskip, and edited by Gary Jaffe.
Perimenopause is when fertility in a female declines, and menstruation occurs less regularly in the years leading up to the final menstrual period, when a female stops menstruating completely and is no longer fertile. The medical definition of menopause is one year without a period and typically occurs between 45 and 55 in Western countries.
The most common cause of vaginal atrophy is the decrease in estrogen which happens naturally during perimenopause, and increasingly so in post-menopause. However this condition can occur in other circumstances that result in decreased estrogen such as breastfeeding and the use of medications intended to decrease estrogen to, for example, treat endometriosis.
The use of hormone replacement therapy (HRT), to lessen the effects of menopause, has shown severe negative effects on the seizure patterns of women with catamenial epilepsy. During perimenopause, women with catamenial epilepsy generally experience an increase in seizure frequency, and HRT use does not change this likelihood. However HRT use after perimenopause has been significantly associated with an increase in seizure frequency and severity. Women progressing through peri- and post-menopause using HRT may be in greater need of anticonvulsant medication monitoring to maintain or reduce seizure occurrence. These same results have not been seen in laboratory counterparts. Adult female rats that have been ovariectomized, a parallel state to menopause, show increased seizure frequency overall. There are, however, several factors that could explain this difference, including ovariectomized rats do not have the analogous brain hormones milieu as menopausal women. Several studies following HRT use in women with catamenial epilepsy have demonstrated more influencable data than animal models, in this case.
During menopause, there are drastic changes in the production of gonadal hormones. Most of the reproductive hormones, including the estrogens, progesterone and testosterone, diminish initially (perimenopause), becoming irregular, often showing wide and unpredictable fluctuations. As menopause progresses, there is cessation of estrogen production by the ovaries. Rosciszewska was one of the first researchers to report an increased risk of seizures during perimenopause, but found a marked decreased risk of seizures during menopause if there was a catamenial relationship. This difference may be associated with the radical fluctuations of estradiol and progesterone during the perimenopausal period than what is experienced during the menopausal period and menstrual cycles of reproductive years. Recall that estrone is the predominant estrogen present during menopause (from subcutaneous fat), and little is known about the effect of estrone specifically on epilepsy. Women with epilepsy who do not follow a catamenial pattern may have an unpredictable increase or decrease in seizure activity in perimenopause and menopause, but women with catamenial epilepsy typically follow a more predictable pattern.
The Centre for Menstrual Cycle and Ovulation Research (CeMCOR) is a health research centre in Vancouver. According to the University of British Columbia, CeMCOR is the only centre in the world that focuses on ovulation and the causes and consequences of ovulation disturbances. CeMCOR is known for research on progesterone-only therapy for menopausal hot flushes, research on perimenopause as distinct from menopause, and for a focus on women's perspectives and self-knowledge.
The beneficial potential of HRT was bolstered in a consensus expert opinion published by The Endocrine Society, which stated that when taken during perimenopause or the initial years of menopause, hormonal therapy carries significantly fewer risks than previously published and reduces all cause mortality in most patient scenarios. The American Association of Clinical Endocrinology released a position statement in 2009 that approved of HRT in the appropriate clinical scenario.
A symptohormonal method of FAM developed at Marquette University uses the ClearBlue Easy fertility monitor to determine the fertile window. The monitor measures estrogen and LH to determine the peak day. This method is also applicable during postpartum, breastfeeding, and perimenopause, and requires less abstinence than other FAM methods. Some couples prefer this method because the monitor reading is objective and is not affected by sleep quality as BBT can be.
The term "perimenopause", which literally means "around the menopause", refers to the menopause transition years, a time before "and" after the date of the final episode of flow. According to the North American Menopause Society, this transition can last for four to eight years. The Centre for Menstrual Cycle and Ovulation Research describes it as a six- to ten-year phase ending 12 months after the last menstrual period.
Estrogen is considered to play a significant role in women’s mental health, with links suggested between the hormone level, mood and well-being. Sudden drops or fluctuations in, or long periods of sustained low levels of estrogen may be correlated with significant mood-lowering. Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of estrogen were stabilized and/or restored.